DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
DiaMedica Therapeutics (Nasdaq: DMAC) announced it will release its third quarter 2024 financial results after market close on November 13th, followed by a conference call on November 14th at 7:00 AM CT. The company, focused on developing treatments for severe ischemic diseases, will provide a business update during the call. Their lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and preeclampsia treatment.
DiaMedica Therapeutics (Nasdaq: DMAC) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il 13 novembre, seguiti da una conferenza telefonica il 14 novembre alle 7:00 AM CT. L'azienda, focalizzata sullo sviluppo di trattamenti per gravi malattie ischemiche, fornirà un aggiornamento commerciale durante la chiamata. Il loro candidato principale DM199 è la prima forma ricombinante farmacologicamente attiva della proteina KLK1, mirata al trattamento dell'ictus ischemico acuto e della preeclampsia.
DiaMedica Therapeutics (Nasdaq: DMAC) anunció que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el 13 de noviembre, seguido de una conferencia telefónica el 14 de noviembre a las 7:00 AM CT. La empresa, centrada en el desarrollo de tratamientos para enfermedades isquémicas severas, proporcionará una actualización comercial durante la llamada. Su candidato principal DM199 es la primera forma recombinante farmacológicamente activa de la proteína KLK1, dirigida al tratamiento del accidente cerebrovascular isquémico agudo y la preeclampsia.
DiaMedica Therapeutics (Nasdaq: DMAC)는 11월 13일 시장 마감 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했으며, 11월 14일 오전 7:00 AM CT에 이어 컨퍼런스 콜이 예정되어 있습니다. 심각한 허혈성 질환 치료제를 개발하는 데 집중하고 있는 이 회사는 통화 중 비즈니스 업데이트를 제공할 것입니다. 그들의 주요 후보 DM199는 급성 허혈성 뇌졸중 및 자간증 치료를 목표로 하는 KLK1 단백질의 첫 번째 약리학적으로 활성화된 재조합 형태입니다.
DiaMedica Therapeutics (Nasdaq: DMAC) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la fermeture du marché le 13 novembre, suivis d'une conférence téléphonique le 14 novembre à 7h00 CT. L'entreprise, qui se concentre sur le développement de traitements pour les maladies ischémiques sévères, fournira une mise à jour commerciale lors de l'appel. Leur candidat principal DM199 est la première forme recombinante pharmaceutiquement active de la protéine KLK1, ciblant le traitement de l'accident vasculaire cerebral ischémique aigu et de la prééclampsie.
DiaMedica Therapeutics (Nasdaq: DMAC) gab bekannt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Börsenschluss am 13. November veröffentlichen wird, gefolgt von einer Telefonkonferenz am 14. November um 7:00 AM CT. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für schwere ischämische Erkrankungen konzentriert, wird während des Gesprächs ein Geschäftsupdate geben. Ihr Hauptkandidat DM199 ist die erste pharmakologisch aktive rekombinante Form des KLK1-Proteins, die auf die Behandlung von akutem ischämischem Schlaganfall und Präeklampsie abzielt.
- None.
- None.
Conference Call details:
Date: |
Thursday, November 14, 2024 |
Time: |
7:00 AM CT / 8:00 AM ET |
Web access: |
|
Dial In: |
(646) 357-8785 |
Conference ID: |
28056 |
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under Investor Relations - Events and Presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 18, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 28056#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106092450/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When will DiaMedica Therapeutics (DMAC) release Q3 2024 earnings?
What time is DiaMedica Therapeutics (DMAC) Q3 2024 earnings call?
What is DiaMedica Therapeutics (DMAC) lead drug candidate?
